publication venue for
- Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy. 2022
- Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.. 23. 2022
- Tumor shrinkage with combination of Alectinib and Trastuzumab in a patient with ALK-rearranged non-small cell lung cancer harboring HER2-amplification as an acquired resistance mechanism to ALK inhibitor therapy. 23. 2022
- Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer. 2021
- Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma.. 21. 2020
- A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.. 19. 2018
- Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.. 19. 2017
- Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.. 19. 2017
- Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery.. 18. 2017
- Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma.. 18. 2016
- Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.. 18. 2016
- Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.. 17. 2016
- Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.. 17. 2015
- Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.. 16. 2015
- Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.. 15. 2014
- Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity.. 11. 2010
- Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.. 9. 2008
- FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy.. 6. 2005
- Promising developments in targeted therapies for non-small-cell lung cancer.. 4. 2002
- Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer.. 3. 2002
- Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients.. 3. 2002
- Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer.. 3. 2001
- Small molecule inhibitors of the epidermal growth factor receptor in patients with non-small-cell lung cancer: an update of clinical data from the 2001 American Society of Clinical Oncology meeting.. 2. 2001
- A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer.. 2. 2000
- Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. 2010
- Computerized tomographic nodule heterogeneity: present and future impact on indications for sublobar resections. 2004
- Prophylactic Cranial Irradiation for Resectable Small-Cell Lung Cancer. 2017
- Current status of mammalian target of rapamycin inhibitors in lung cancer. 2005
- Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. 2004